Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 14/20 | 0.46 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.43 |
| ▸ | ULK1 | O75385 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL802725 | 0.86 | IGF1R (0.46) | IGF1RNEK1ULK1 | |
| SCHEMBL801689 | 0.86 | IGF1R (0.48) | IGF1RNEK1 | |
| SCHEMBL805531 | 0.85 | IGF1R (0.47) | IGF1RNEK1ULK1 | |
| SCHEMBL802386 | 0.76 | IGF1R (0.50) | IGF1RNEK1 | |
| SCHEMBL802688 | 0.75 | IGF1R (0.63) | IGF1RNEK1ULK1 | |
| SCHEMBL801760 | 0.74 | IGF1R (0.47) | IGF1RNEK1 | |
| SCHEMBL12620041 | 0.73 | IGF1R (0.47) | IGF1RNEK1ULK1 | |
| SCHEMBL805546 | 0.71 | IGF1R (0.47) | IGF1RNEK1ULK1 | |
| SCHEMBL802079 | 0.70 | AURKA (0.57) | IGF1RPAK4 | |
| SCHEMBL802308 | 0.69 | AURKA (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | IGF1R 293/4885NEK1 270/4885ULK1 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.